1. Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
   Qihui Shao et al, 2021, Frontiers in Pharmacology CrossRef
2. Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: A Prospective Observational Study
   A. V. Vlasova et al, 2023, Safety and Risk of Pharmacotherapy CrossRef
3. Association of genetic polymorphisms ofCYP2E1, NAT2, GSTandSLCO1B1with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis
   Seungwon Yang et al, 2019, BMJ Open CrossRef
4. Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients
   Supharat Suvichapanich et al, 2019, Antimicrobial Agents and Chemotherapy CrossRef
5. Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review
   Tesemma Sileshi et al, 2022, Pharmacogenomics and Personalized Medicine CrossRef
6. Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?
   Carola Oelofse et al, 2023, Clinical and Translational Science CrossRef
7. Rifampicin Transport by OATP1B1 Variants
   Carlijn H. C. Litjens et al, 2020, Antimicrobial Agents and Chemotherapy CrossRef
8. Advances in the Study of Related Factors of Methimazole-Induced Liver Injury
   丽芹 张, 2022, Advances in Clinical Medicine CrossRef
9. Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav–Related Liver Injury
   Mohammad Alshabeeb et al, 2022, Frontiers in Pharmacology CrossRef